Drug combos could be "practice changing" for advanced breast cancer

12/8/2011 | MSNBC · HealthDay News

Two experimental drug combinations extended survival in women with advanced breast cancer, according to studies presented at the San Antonio Breast Cancer Symposium and published in The New England Journal of Medicine. In one study, women with HER2-positive breast cancer treated with Genentech's Herceptin, chemotherapy and experimental drug pertuzumab lived an average of 18.5 months without recurrence, compared with 12.4 months in the group receiving only Herceptin and chemotherapy. Genentech applied for FDA approval of pertuzumab this week.

View Full Article in:

MSNBC · HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI